- Home
- ACHV
as 09-05-2025 4:00pm EST
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 131.3M | IPO Year: | N/A |
| Target Price: | $16.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.84 - $5.31 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Achieve Life Sciences Inc. News
ACHV Breaking Stock News: Dive into ACHV Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires
2 months ago
Sector Update: Health Care
MT Newswires
2 months ago
Update: Achieve Life Sciences Shares Fall After Pricing $45 Million Offering
MT Newswires
2 months ago
Top Midday Decliners
MT Newswires
2 months ago
Traders Digest Fed's Preferred Inflation Gauge as US Equity Futures Gain Pre-Bell
MT Newswires
2 months ago
Top Premarket Decliners
MT Newswires
2 months ago
Achieve Life Sciences Prices $45 Million Public Offering
GlobeNewswire
2 months ago
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
Compare ACHV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACHV Achieve Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.